 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...3233343536373839404142...100101» |
- letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
Short-term preoperative endocrine therapy allows to estimate and revert patient prognosis with further treatment plan correction in HR+ HER2- early breast cancer patients. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5949;
HR+ HER2- BC pts stages I-II any level of Ki67 independent from grade have received P-ET (letrozole (L)/anastrozole (A)/tamoxifen (TAM)) no less than 2 weeks until surgery in MCSC named after A.S. Loginov. In HR+ HER2- early BC pts short-term P-ET simply allows to estimate pts prognosis and further AT strategy proper planning: to identify the pts population of whom CT can be avoided while maintaining treatment efficacy with a better quality of life (42% pts of IIT) (1), to radically change the planned AT to achieve optimal treatment results (2,4% pts of IIT) (2).
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus letrozole in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5532;
P2
Conclusions Anlotinib plus letrozole showed a promising efficacy with a favorable toxicity profile for patients with platinum-resistant recurrent ovarian cancer. The trial is ongoing and more data will be provided in the future.
- Verzenio (abemaciclib) / Eli Lilly
A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. (Available On Demand; 401) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5466;
P2
These results compare favorably to published outcomes of neoadjuvant chemotherapy in LGSOC. Further studies are planned to explore this new treatment option in a larger study population.
- Kisqali (ribociclib) / Novartis
Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5333;
P3
Pts with ctDNA+/TKa+ are strongly enriched for non-responders. TKa and ctDNA capture different features of tumor biological activity and their combination warrants further evaluation in relation to other treatments, settings, and diseases.
- letrozole / Generic mfg., tamoxifen / Generic mfg., exemestane / Generic mfg.
Polypharmacy and premature aromatase inhibitor (AI) discontinuation in older women with breast cancer. (Available On Demand; 351) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4743;
P=N/A
Increased prescription medication usage at AI initiation was associated with decreased risk of premature discontinuation of AI. Further research is needed to evaluate this interaction and identify characteristics that impact AI persistence in older women with breast cancer.
- Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA). (Available On Demand; 378b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3305;
P3
Achievement of ovarian suppression will be defined as ≥ 90% of subjects with luteinizing hormone (LH) levels < 4 IU/L at Week 6. Secondary endpoints include suppression of LH, E2 (< 20 pg/mL for tamoxifen cohort and < 2.72 pg/mL for AI cohort) and absence of menses at weeks 6, 12, 24, 36, and 48.
- dalpiciclib (SHR6390) / Jiangsu Hengrui Medicine
Primary analysis of MUKDEN 01: A multicenter, single-arm, prospective, phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple-positive breast cancer. (Available On Demand; 359) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3285;
P2
The combined therapy was also well-tolerated and provided a chemo-sparing neoadjuvant approach for TPBC patients. To our knowledge, this is the first study to evaluate the therapeutic efficacy of a chemo-free neoadjuvant treatment with HER2 TKI pyrotinib and letrozole plus CDK4/6 inhibitor dalpiciclib for TPBC patients.
- Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis. (Available On Demand; 307) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3233;
The sequential use of aromatase inhibitors may be the optimal treatment mode for hormone receptor-positive postmenopausal early breast cancer patients. In addition, the three kinds of aromatase inhibitors achieved roughly equal efficacy, but caused different types of SAEs.
- amcenestrant (SAR439859) / Sanofi
AMEERA-4: A preoperative window-of-opportunity (WOO) study to assess the pharmacodynamic (PD) activity of amcenestrant or letrozole in postmenopausal patients with ER+/HER2− primary breast cancer. (Available On Demand; 300) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3226;
P2, P3
Both doses of amcenestrant demonstrated robust Ki67 reductions, strongly engaged the ER target, and continued to show a favorable safety profile in an early breast cancer population, consistent with previous published reports. Based on PD activity and safety, and emerging results from other ongoing amcenestrant trials, the 200 mg QD dose of amcenestrant was selected for our ongoing study in the adjuvant setting; AMEERA-6 (NCT05128773).
- Ibrance (palbociclib) / Pfizer
Efficacy and safety of palbociclib in treatment of HR-positive advanced breast cancer patients: A single center real-world experience. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1258;
Based on PD activity and safety, and emerging results from other ongoing amcenestrant trials, the 200 mg QD dose of amcenestrant was selected for our ongoing study in the adjuvant setting; AMEERA-6 (NCT05128773). In the present study, Palbociclib + Letrozole reported good clinical response at the end of treatment duration with a manageable tolerability profile in the Indian population.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1232;
In this study, we demonstrated the tendency that overweight patients with metastatic breast cancer may benefit more from CDK4/6 inhibitors in term of PFS from interim analyses of our data. Similar toxicity rates and adverse events were observed in all BMI groups with CDK4/6 inhibitors plus ET.
- FCN-437 / Fosun Pharma
The CDK4/6 inhibitor FCN-437c plus letrozole for the treatment of HR+/HER2– advanced breast cancer: Updated results from a phase 1b study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1222;
P1/2
FCN-437c plus letrozole was well tolerated and demonstrated antitumor activity in patients with previously untreated HR+/HER2– ABC. FCN-437c in combination with NSAI as the first-line treatment for HR+/HER2– ABC will be further investigated in a phase 3 trial.
- maveropepimut-S (MVP-S) / IMV Inc
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC). (Available On Demand; 490a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1205;
P1
Biomarker objectives are to evaluate for each treatment arm: 1) systemic type I survivin-specific immune response, as measured by IFN-γ ELISPOT; 2) changes in immune environment by GeoMx digital spatial genomic profiling; 3) and changes in tumor infiltrating lymphocytes (TILs) and Ki67. These data will be used to identify the most immunogenic MVP-S combination therapy for study in phase II trial powered to assess clinical outcome (pCR).
- Piqray (alpelisib) / Novartis
EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) +/- dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL). (Available On Demand; 484a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1193;
P2
A biomarker analysis is planned as an exploratory objective. Recruitment is ongoing with enrollment planned in 56 sites across 8 countries; completion of primary data collection is anticipated in 2023.
- dalpiciclib (SHR6390) / Jiangsu Hengrui Medicine
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2- advanced breast cancer: A phase Ib study. (Available On Demand; 444) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1153;
P1/2
The recommended phase 3 dose of dalpiciclib was 150 mg. Together with the promising anti-tumor activity observed with the combination therapy in HR+/HER2- ABC, further trials are warranted.
- Ibrance (palbociclib) / Pfizer, inavolisib (GDC-0077) / Roche
Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC). (Available On Demand; 430) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1139;
P1, P3
The safety profile of pts on study treatment with inavolisib alone or in combo with endocrine-based anticancer therapies for ≥1 year was similar to that reported for the overall study population. Updated data will be presented.
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Aromatase inhibitors for breast cancer therapy: Analysis of real-world FAERS data. (Available On Demand; 429) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1138;
Updated data will be presented. The findings in this study highlight trends for selected AEs with various AI regimens, provide further insights, and help guide therapeutic decisions for patients with HRPBC.
- Piqray (alpelisib) / Novartis
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study. (Available On Demand; 396) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1103;
In Cohort B, both ≤ 6-mo and >6-mo groups had high median ctDNA fractions and similar tumor mutation profiles. Additional ctDNA and tissue analyses are needed to elucidate the correlation between ALP + ET efficacy and treatment timing and baseline genomic complexity.
- Kisqali (ribociclib) / Novartis
Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2. (Available On Demand; 395) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1101;
P3
In this exploratory analysis of ML-2, OS benefit was maintained in pts with HR+/HER2− ABC who required mod from the recommended starting dose of RIB (600 mg/d 3 wk on/1 wk off). No relationship was observed between OS and RIB dose reduction or RDI2; OS benefit with RIB was observed in all groups.
- Ibrance (palbociclib) / Pfizer
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1088;
P3
Pts receiving PAL+LET had numerically longer OS compared to PBO+LET, but the results were not statistically significant. Funding: Pfizer Inc (NCT01740427)
- | letrozole / Generic mfg.
Journal: Letrozole promotes the expression of integrin αvβ3 and HOXA10 in endometrium of endometriosis. (Pubmed Central) - Apr 27, 2022
Animals were treated with letrozole at 2ug/kg of body weight, intragastric administration for 15 consecutive days. Letrozole increased the expression of αvβ3 and HOXA10 in the endometriosis model and endometrial receptivity.Abbreviations: WOI: window of implantation; RGD: Arg-Gly-Asp; HOX: homeobox; E2: estradiol; SPF: specific pathogen-free.
- || letrozole / Generic mfg., everolimus / Generic mfg.
P2 data, Journal: A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. (Pubmed Central) - Apr 27, 2022
EL and MT demonstrated clinically meaningful efficacy in recurrent EC patients. The higher PFS observed in chemo-naïve patients is worthy of confirmation in future studies.
- | Ibrance (palbociclib) / Pfizer
Journal: Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. (Pubmed Central) - Apr 27, 2022
NEOPAL suggests that a neoadjuvant letrozole-palbociclib strategy may allow sparing chemotherapy in some patients with luminal breast cancer while allowing good long-term outcomes. Larger confirmatory studies are needed.
- | Reimbursement, Journal, HEOR, Medicare: Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study. (Pubmed Central) - Apr 26, 2022
Larger confirmatory studies are needed. Although there was no significant difference in physical HRQoL scores between AET agents, anastrozole and tamoxifen were associated with better mental HRQoL scores.
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Journal, Monotherapy: Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma. (Pubmed Central) - Apr 26, 2022
No evident difference was observed in 1-, 3-, or 5-year survival rates between the two groups, while the 3-5-year recurrence rate was obviously lower, and the improvement of blood lipid indices was significantly better in the research group compared with the control group. LTZ alone or in sequence with TAM is effective and safe for the treatment of BC, which can significantly improve the prognosis and blood lipid indices of BC patients.
- | letrozole / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients. (clinicaltrials.gov) - Apr 26, 2022
P4, N=236, Not yet recruiting, Sponsor: Dubai Fertility Center
LTZ alone or in sequence with TAM is effective and safe for the treatment of BC, which can significantly improve the prognosis and blood lipid indices of BC patients. Trial completion date: Nov 2023 --> Apr 2024 | Initiation date: Feb 2022 --> Aug 2022 | Trial primary completion date: Sep 2023 --> Feb 2024
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial completion: Pharmacokinetics and Hepatic Safety of EGCG (clinicaltrials.gov) - Apr 25, 2022
P1, N=36, Completed, Sponsor: Yale University
Trial completion date: Nov 2023 --> Apr 2024 | Initiation date: Feb 2022 --> Aug 2022 | Trial primary completion date: Sep 2023 --> Feb 2024 Recruiting --> Completed
- | SP600125 / BMS
Journal: IL-15 Participates in the Pathogenesis of Polycystic Ovary Syndrome by Affecting the Activity of Granulosa Cells. (Pubmed Central) - Apr 23, 2022
The results indicate that IL-15 is involved in the pathogenesis of PCOS potentially by affecting survival, the inflammation state and steroidogenesis of granulosa cells. The practical significance of this association between IL-15 and the pathogenesis of PCOS needs further investigation.
- | letrozole / Generic mfg.
Biomarker, Retrospective data, Journal: Utility of Blood Markers for Predicting Outcomes of Fertility Preservation in Patients With Breast Cancer. (Pubmed Central) - Apr 23, 2022
In total, 91 patients with breast cancer who had undergone COS using a letrozole-combined gonadotropin-releasing hormone (GnRH) antagonist protocol before chemotherapy were enrolled retrospectively in a single tertiary hospital...Protocols to acquire more mature oocytes, such as the dual-trigger approach, could be recommended for patients with breast cancer with MPV<10.15. Furthermore, a higher dose of gonadotropins was considered to obtain more oocytes in patients with MPV/PC<0.41.
- | letrozole / Generic mfg.
Journal: A Randomized Cohort Study: Is It Worth the Time to Receive Antiandrogenic Pretreatment Before Ovulation Induction for Women With Polycystic Ovary Syndrome? (Pubmed Central) - Apr 23, 2022
Randomization to direct ovulation induction of letrozole (letrozole group) or ethinylestradiol/cyproterone acetate (EE/CPA) for 3 months and subsequent letrozole-induced ovulation (EE/CPA+ letrozole group)...There is no benefit to perform antiandrogenic therapy before ovulation induction in patients with PCOS in clinical practice. www.clinicaltrials.gov, identifier ChiCTR1900022839.
- | Herceptin (trastuzumab) / Roche
Journal: Assessment of Breast Cancer Management in Sub-Saharan Africa. (Pubmed Central) - Apr 22, 2022
Socioeconomic and cultural barriers and system delays persist. Workforce expansion must be prioritized to improve quality of care to improve outcomes.
- || Venclexta (venetoclax) / Roche, AbbVie, Ibrance (palbociclib) / Pfizer
P1 data, Review, Journal: PALVEN: phase 1b trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. (Pubmed Central) - Apr 22, 2022
P1b
The primary objective is to identify the maximum tolerated dose and determine the recommended phase 2 dose for palbociclib, letrozole and venetoclax combination therapy. Clinical Trial Registration: NCT03900884 (ClinicalTrials.gov).
- | metformin / Generic mfg.
Preclinical, Journal: Histomorphological Changes in a Rat Model of Polycystic Ovary Syndrome and the Contribution of Stevia Leaf Extract in Modulating the Ovarian Fibrosis, VEGF, and TGF-β Immunoexpressions: Comparison with Metformin. (Pubmed Central) - Apr 22, 2022
SLE showed potential therapeutic merits in letrozole-induced PCOS via anti-inflammatory, antioxidant, anti-fibrotic, and angiogenesis regulating mechanisms. Its effects were almost comparable to metformin, and the combination of both has no further synergistic effect.
- Management of the Side Effect of Hormone Therapy () (RM 3(Walker Hall 1)) - Apr 22, 2022 - Abstract #GBCC2022GBCC_186;
This is crucial to increase treatment adherence and quality of life during adjuvant endocrine therapy. An individualized approach when choosing an intervention to control these symptoms is likely to have better chances of achieving a positive effect on oncological outcomes and quality of life.
- Must-have Knowledge about GnRH Agonist for Patients with Breast Cancer (RM 5(Art Hall)) - Apr 22, 2022 - Abstract #GBCC2022GBCC_164;
In the light of increased morbidity with aromatase inhibitors and in the context of the reported data of the SOFT/TEXT trials, most patients are optimally treated with tamoxifen and ovarian function suppression (OFS). However, the option of aromatase inhibitors and OFS should be discussed on an individual basis.
- Verzenio (abemaciclib) / Eli Lilly
Verzenio, Potent CDK4/6 Inhibitor, How to Optimize HR+/HER2- mBC Patient with CDK4/6 Inhibitors (RM 1(Vista 1+2)) - Apr 22, 2022 - Abstract #GBCC2022GBCC_145;
The median PFS, the primary endpoint of the study, showed a statistically significant difference (p= 0.00021) with a hazard rate of 0.54 (95% CI: 0.41 to 0.72), demonstrating the efficacy of the drug.The Monarch 2 trial also evaluated the efficacy of abemaciclib combined with fulvestrant in patients with advanced BC which progressed despite hormone therapy...Furthermore, at our hospital we have established a patient support center providing easy access to outpatient counseling by nurses with relevant expertise, peer support from other breast cancer patients, and counseling by clinical psychologists to address the various psychological, social, and physical issues that may arise during treatment for advanced breast cancer.The present seminar will cover the history of the development of cancer treatments in Japan, introduce data from the Monarch 2 and 3 clinical trials, review cases of abemaciclib use in actual clinical practice, and examine how we deal with side effects in our practice. I would also be happy to share with our Korean colleagues the evaluation of abemaciclib in Japan and discuss the measures implemented against its various adverse effects.
- Ibrance (palbociclib) / Pfizer
Maximizing Clinical Outcome in HR+HER2- Metastatic Breast Cancer Patients: Palbociclib & CDK4/6 Inhibitors in Real-world Practice (RM 1(Vista 1+2)) - Apr 22, 2022 - Abstract #GBCC2022GBCC_42;
Median OS was not reached in Palbociclib+letrozole arm while letrozole showed mOS of 43.1 month (HR= 0.66; 95% CI 0.53-0.82, P= 0.0002). In the real-world setting, palbociclib showed its efficacy in heterogeneous populations.3)In addition, palbociclib is the only CDK4/6 inhibitor that was approved for male breast cancer patients with HR(+) advanced breast cancer based on real-world data.In summary, palbociclib in combination with endocrine therapy is an effective and safe treatment option in patients with HR(+) advanced breast cancer with various co-morbidities in real-world practice.
- Trials of ER(+) Cancer in Japan (RM 5(Art Hall)) - Apr 22, 2022 - Abstract #GBCC2022GBCC_36;
Unfortunately, this study was stopped due to safety concern, mainly liver toxicities and interstitial lung disease.From now on, both escalation and de-escalation are important if we select appropriate patients. Individualization is most essential, and we need to conduct clinical trials to answer many clinical questions.
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (clinicaltrials.gov) - Apr 22, 2022
P2, N=198, Recruiting, Sponsor: MedSIR
Individualization is most essential, and we need to conduct clinical trials to answer many clinical questions. Trial completion date: Jan 2023 --> Apr 2023 | Trial primary completion date: Aug 2022 --> Nov 2022
- | Mifeprex (mifepristone) / Danco Laboratories
New P4 trial, Head-to-Head: The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy (clinicaltrials.gov) - Apr 21, 2022
P4, N=144, Not yet recruiting, Sponsor: KK Women's and Children's Hospital
- | letrozole / Generic mfg.
Retrospective data, Journal: Progestin-primed ovarian stimulation protocol with or without letrozole for patients with normal ovarian reserve: a retrospective cohort study. (Pubmed Central) - Apr 21, 2022
Compared with PPOS protocol alone, letrozole combined with PPOS can achieve similar embryo and pregnancy outcomes while reducing the amount of Gn and MPA, which has a higher cost performance and is worth promoting. Stage and number of embryos transfer are risk factors for clinical pregnancy rate.
- || letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. (Pubmed Central) - Apr 21, 2022
We present here an assay suitable for the simultaneous measurement of serum levels of all third-generation AIs and ultra-low levels of estrogens, providing a powerful new tool to study drug efficacy and compliance. The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below the threshold of detection for most routine assays, but still require suppression.
- | letrozole / Generic mfg.
Journal: Follicular Fluid-Derived Exosomal MicroRNA-18b-5p Regulates PTEN-Mediated PI3K/Akt/mTOR Signaling Pathway to Inhibit Polycystic Ovary Syndrome Development. (Pubmed Central) - Apr 21, 2022
A rat model of PCOS was established by letrozole and then injected with miR-18b-5p-modified exosomes...miR-18b-5p produced by FF-derived exosomes reduces PTEN expression and promotes the activation of the PI3K/Akt/mTOR signaling pathway to improve PCOS. Based on that, circulating miR-18b-5p levels can contribute to the progression of PCOS complications.
- | letrozole / Generic mfg.
Preclinical, Journal: Mogroside V Improves Follicular Development and Ovulation in Young-Adult PCOS Rats Induced by Letrozole and High-Fat Diet Through Promoting Glycolysis. (Pubmed Central) - Apr 21, 2022
Western blotting and immunohistochemistry analysis showed that MV restored the expression of lactate dehydrogenase A (Ldha), hexokinase 2 (Hk2) and pyruvate kinase M2 (Pkm2). Collectively, these findings indicated that MV could effectively improve the ovarian microenvironment by upregulating the expression of LDHA, HK2 and PKM2 in granulosa cells and enhancing lactate and energy production, which may contribute to follicle development and ovulation of young-adult PCOS rats.
- | letrozole / Generic mfg., spironolactone / Generic mfg.
Journal: Female Pelvic Conditions: Polycystic Ovary Syndrome. (Pubmed Central) - Apr 21, 2022
Gonadotropin-releasing hormone analogues also are used to induce ovulation. (This is an off-label use of letrozole and gonadotropin-releasing hormone analogues.).
- || Kisqali (ribociclib) / Novartis
Clinical data, Review, Journal: Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection. (Pubmed Central) - Apr 21, 2022
In conclusion, ribociclib with letrozole or with fulvestrant is effective for the entire spectrum of patients with HR+ BC in the advanced setting. Ribociclib has all the characteristics of an innovative drug able to change the clinical practice and most BC patients' prognoses.
- | Trial completion date: Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (clinicaltrials.gov) - Apr 21, 2022
P4, N=231, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
Ribociclib has all the characteristics of an innovative drug able to change the clinical practice and most BC patients' prognoses. Trial completion date: Aug 2024 --> Aug 2022
- | letrozole / Generic mfg.
Enrollment open: Live Birth After Letrozole-stimulated Cycles Versus Hormone Replacement Treatment Cycles for the First Frozen Embryo Transfer in Women With PCOS (clinicaltrials.gov) - Apr 21, 2022
P=N/A, N=1078, Recruiting, Sponsor: Reproductive & Genetic Hospital of CITIC-Xiangya
Trial completion date: Aug 2024 --> Aug 2022 Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Preclinical, Journal: Bushen Jieyu Tiaochong Formula reduces apoptosis of granulosa cells via the PERK-ATF4-CHOP signaling pathway in a rat model of polycystic ovary syndrome with chronic stress. (Pubmed Central) - Apr 20, 2022
Moreover, BJTF could improve behavioral performance by regulating cerebral monoamine neurotransmitters in this rat model. These findings provide a new perspective for treating PCOS related to psychological stress using TCM.
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Clinical, Retrospective data, Journal: Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. (Pubmed Central) - Apr 20, 2022
Older monotherapies that continue to be used in RCTs in comparator groups, such as anastrozole (251 of 252) and letrozole (252), fell to the bottom of the rankings...In this network meta-analysis study, combination therapies appeared to be associated with better outcomes than monotherapies in the treatment of HR-positive, ERBB2-negative MBC. These findings suggest that IT-NMA is a promising method for longitudinal ranking of anticancer regimens from RCTs with different end points, sparse interconnectivity, and decades-long timeframes.